san jose collage
San Jose
Serving San Jose, California (Santa Clara County)Vol. 1, No. 23
Medicine

A South San Francisco pill nearly doubled the time before advanced breast cancer worsened, and the FDA just approved it

Genentech’s Wilserdly (giredestrant) targets tumors with a common resistance mutation.  A second decision, for early-stage cancer, is due Nov. 30.

ShareFacebookXEmail
Illustration of a white unbranded pill bottle and tablets on a tray beside a pink breast-cancer awareness ribbon on a sunlit white counter, with a blurred blood-test tube rack in the background.
An AI-generated illustration of a breast cancer pill and blood test. — Illustration: AI-generated for Daily News

Some patients with advanced breast cancer that has stopped responding to hormone therapy have a new all-pill option.  The Food and Drug Administration approved Wilserdly (giredestrant), made by South San Francisco-based Genentech, on Nov. 16.  It is taken once a day with everolimus, an existing cancer pill.

Patients first need a blood test showing their tumor carries an ESR1 mutation.  Genentech says the drug should reach U.S. pharmacies in the coming weeks, and that some commercially insured patients may pay as little as $0 through its co-pay program.

Who it’s for

About 70% of breast cancers are fueled by the hormone estrogen, according to Dana-Farber Cancer Institute.  These “ER-positive” cancers are usually treated with drugs that block estrogen, but over time many tumors stop responding.  Up to 40% of patients with this type of advanced cancer develop ESR1 mutations, a change in the estrogen-receptor gene that drives that resistance, Genentech said.

The approval covers adults whose ER-positive, HER2-negative cancer has spread or can’t be removed, has an ESR1 mutation and has grown during or after hormone therapy.  The FDA also authorized the blood test used to find the mutation.

How it works

Estrogen drives these cancers by latching onto a protein inside the cell called the estrogen receptor.  Giredestrant is a SERD, short for selective estrogen receptor degrader:  it blocks the receptor and also tags it for the cell to destroy.  Everolimus blocks mTOR, a separate growth signal, so the pair attacks the cancer along two routes.

What the trial showed

In the evERA trial of 373 adults, 207 had ESR1 mutations.  In that group, according to the FDA:

  • The cancer took a median of 10 months to worsen on giredestrant plus everolimus, versus 5.5 months on standard hormone therapy plus everolimus.
  • The risk of the cancer worsening or death fell 62%.
  • 27% saw their tumors shrink, versus 14%.
  • It is too early to know whether patients live longer.

Common side effects included mouth sores, rash, fatigue, diarrhea, muscle pain, lung inflammation and nausea, and the label warns of a slow heart rate, the FDA said.  Dr. Erica Mayer of Dana-Farber, who led the trial, said the drug offers “prolonged disease control through a fully oral therapeutic option.”

What’s next

The FDA is also reviewing giredestrant for early-stage breast cancer after surgery, with a decision due Nov. 30, Genentech said.  It would be the first new hormone therapy for that use in more than 20 years.

Source:  FDA, Nov. 16, 2026; Genentech, Nov. 16, 2026; Dana-Farber Cancer Institute, Nov. 16, 2026.

Drafted by AI from the linked public source. Approved by a Daily News Editor.

Sources and documents